Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| renal alpha-intercalated cell | 5 studies | 41% ± 5% |
Insufficient scRNA-seq data for expression of NUPR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 100% | 368.59 | 652 / 653 | 83% | 21.75 | 502 / 605 |
| prostate | 93% | 155.28 | 229 / 245 | 70% | 13.88 | 351 / 502 |
| breast | 72% | 78.74 | 332 / 459 | 76% | 23.10 | 853 / 1118 |
| ovary | 45% | 30.36 | 81 / 180 | 86% | 36.79 | 371 / 430 |
| kidney | 100% | 338.08 | 89 / 89 | 12% | 5.62 | 112 / 901 |
| pancreas | 69% | 39.36 | 226 / 328 | 34% | 4.24 | 60 / 178 |
| brain | 91% | 105.29 | 2398 / 2642 | 5% | 0.42 | 32 / 705 |
| stomach | 86% | 101.95 | 308 / 359 | 8% | 1.58 | 24 / 286 |
| lung | 64% | 35.24 | 369 / 578 | 29% | 5.37 | 339 / 1155 |
| uterus | 48% | 23.49 | 81 / 170 | 35% | 6.24 | 162 / 459 |
| adrenal gland | 71% | 67.97 | 184 / 258 | 1% | 0.66 | 3 / 230 |
| blood vessel | 65% | 58.43 | 870 / 1335 | 0% | 0 | 0 / 0 |
| bladder | 38% | 13.90 | 8 / 21 | 26% | 4.17 | 131 / 504 |
| esophagus | 45% | 25.32 | 650 / 1445 | 17% | 2.46 | 31 / 183 |
| skin | 60% | 33.57 | 1082 / 1809 | 0% | 0.05 | 2 / 472 |
| intestine | 44% | 22.65 | 422 / 966 | 7% | 1.11 | 35 / 527 |
| muscle | 42% | 27.36 | 334 / 803 | 0% | 0 | 0 / 0 |
| adipose | 41% | 21.87 | 491 / 1204 | 0% | 0 | 0 / 0 |
| heart | 36% | 19.86 | 308 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 36% | 6.24 | 16 / 45 |
| spleen | 30% | 11.02 | 73 / 241 | 0% | 0 | 0 / 0 |
| liver | 27% | 12.49 | 61 / 226 | 1% | 0.06 | 3 / 406 |
| peripheral blood | 13% | 10.60 | 124 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006974 | Biological process | DNA damage response |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0045786 | Biological process | negative regulation of cell cycle |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0009267 | Biological process | cellular response to starvation |
| GO_0051726 | Biological process | regulation of cell cycle |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0005634 | Cellular component | nucleus |
| Gene name | NUPR2 |
| Protein name | Nuclear protein 2 (Nuclear transcriptional regulator 1-like protein) (Nuclear transcriptional regulator protein 2) |
| Synonyms | NUPR1L |
| Description | FUNCTION: Acts as a transcriptional repressor by inhibiting gene expression at the NUPR1 promoter in a p53/TP53-dependent manner in cancer cells . Involved in the G1 cell cycle arrest, and in a decrease in cell viability and cell proliferation . Plays a role as a negative regulator of the protumoral factor NUPR1 . . |
| Accessions | A6NF83 ENST00000329309.4 |